Letrozole is used for: Breast cancer.
Recorded in the NepalDoc medicine catalog for Letrozole.
Letrozole tablet is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
From the U.S. FDA-approved label for Letrozole. Full label: DailyMed.
Letrozole tablet is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival (DFS) in patients treated with letrozole tablets for a median of 60 months.
From the U.S. FDA-approved label for Letrozole. Full label: DailyMed.
Letrozole tablets are taken orally without regard to meals: Recommended dose: 2.5.mg once daily Patients with cirrhosis or severe hepatic impairment: 2.5 mg every other day 2.1 Recommended Dose The recommended dose of letrozole tablet is one 2.5 mg tablet administered once a day, without regard to meals. 2.2 Use in Adjuvant Treatment of Early Breast Cancer In the adjuvant setting, the optimal duration of treatment with letrozole is unknown. In both the adjuvant study and the post approval adjuvant study, median treatment duration was 5 years.
Directions from the U.S. FDA-approved label for Letrozole — your doctor or pharmacist may advise differently.
Pregnancy: Letrozole can cause fetal harm. Pregnancy: Letrozole can cause fetal harm. Known hypersensitivity to the active substance, or to any of the excipients. Known hypersensitivity to the active substance, or to any of the excipients. Pregnancy Known hypersensitivity to the active substance, or to any of the excipients
Excerpt from the U.S. FDA-approved label for Letrozole. Talk to a pharmacist or doctor before use.
Decreases in bone mineral density may occur. Consider bone mineral density monitoring Increases in total cholesterol may occur. Consider cholesterol monitoring. Fatigue, dizziness and somnolence may occur. Exercise caution when operating machinery Embryo-Fetal Toxicity: Can cause fetal harm when administered to pregnant women. Obtain a pregnancy test in females of reproductive potential. Advise females of reproductive potential to use effective contraception 5.1 Bone Effects Use of letrozole may cause decreases in bone mineral density (BMD). Consideration should be given to monitoring BMD.
Warnings and precautions excerpt from the U.S. FDA-approved label for Letrozole — not a complete list. Talk to a pharmacist or doctor before use.
The following adverse reactions are discussed in greater detail in other sections of the labeling. Bone effects Increases in cholesterol Fatigue and Dizziness The most common adverse reactions (greater than 20%) were hot flashes, arthralgia; flushing, asthenia, edema, arthralgia, headache, dizziness, hypercholesterolemia, sweating increased, bone pain and musculoskeletal.
Excerpt from the U.S. FDA-approved label for Letrozole — not a complete list. Talk to a pharmacist or doctor about side effects.
5 brands · 5 makers in the NepalDoc catalog — see the full Letrozole guide →
What is Mamazol?
Mamazol 2.5mg Tablet is a Letrozole medicine made by Khandelwal Laboratories Pvt Ltd. It comes as 2.5mg Tablet.
What is Mamazol used for?
Letrozole is used for Breast cancer.
What is the generic name of Mamazol?
The generic name of Mamazol is Letrozole.
Which brands of Letrozole are available in Nepal?
5 brands of Letrozole are listed in the NepalDoc catalog, from 5 makers — including Fempro 2.5mg Tablet, Lerozol 2.5 mg Tablet, Letoripe 2.5mg Tablet, Trozet 2.5mg Tablet.
What are the side effects of Letrozole?
The following adverse reactions are discussed in greater detail in other sections of the labeling.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
